AstraZeneca - December 2021 - case study 1

Project Aims and Objectives

• Proactive identification & review of “high risk” patients as defined by the NRAD criteria to optimise asthma management:
• Reduce SABA use in patients who may be over-reliant on their SABA inhaler.
• Identify Asthma patients who may be inappropriately prescribed high dose ICS therapy.
• Implementation of AAC recommendations: FeNO testing to support appropriate interventions, including referral to severe asthma clinics where appropriate
• Simplify & standardise asthma reviews through Implementation of LungHealth, an AI-based computer guided consultation tool

Achievements & Milestones

• Identifying High risk asthma: ≥6 SABA per year plus another NRAD ‘at risk’ criteria.
• Identifying Overtreated asthma: high dose ICS therapy (1,00-2,000+ beclomethasone equiv. ICS), where there is potential for down-titration of the patient’s medication.
• Allow appropriate interventions to avoid potential exacerbations or hospital admissions, including an enhanced self-management plan.
• Patients are provided education support from local asthma specialists, as well as access to SENTINEL info & MyAsthma.
• Establishment of an MDT for difficult-to-treat asthma patients.

Patient Benefit

• Over 1000 patients in Greater Manchester received asthma reviews to improve asthma diagnosis and management through STARRS-GM
• A large portion of the patients reviewed have gone on to receive a Personalised Asthma Action Plan (PAAP) as part of their care.
• Allow appropriate interventions to avoid potential exacerbations or hospital admissions, including an enhanced self-management plan.

GB-49317 October 2023